The first-in-human CRO for the Americas. Cost, timeline, FDA acceptance, guarantees, and who you would actually work with: specific answers for first-in-human CRO selection.
bioaccess® has run more than 50 first-in-human (FIH) programs across 19 Latin American & Caribbean countries since 2010. Co-founded by Pedro Martinez-Clark, MD (Harvard) and William W. O'Neill, MD (MSCAI; first transcatheter aortic valve replacement in North America, JACC 2022). Built specifically for MedTech, biopharma, and radiopharma startups — not for big pharma Phase III work.
A U.S. CRO runs your first-in-human study at U.S. sites. bioaccess® keeps U.S. regulatory strategy (FDA Pre-Sub, IND/IDE) and sponsor-facing project leadership in Miami, and executes the study across Latin America. Budget depends on study design; we provide a study-specific quote. Ethics approval varies by study (Panama up to 20 business days, 10 expedited, under Decreto Ejecutivo 21/2026). Clinical data is FDA-bridgeable under 21 CFR 812.28 (devices) and 312.120 (drugs and biologics); FDA acceptance is decided case by case.
Budget depends on study design; we provide a study-specific quote. The exact number depends on device class, country, and study duration. Use our 2-minute calculator for a personalized estimate.
See your timeline & cost in 2 minutes
Written 12-month timeline guarantee under FIH-12™. If we miss it for reasons within our control, we credit 100% of our project-management and monitoring fees until LPLV. Full terms in your proposal. No change orders, no renegotiation. We're not aware of another CRO offering a written timeline guarantee for first-in-human work — if you find one, tell us and we'll match it.
Probably yes. 50+ MedTech and biopharma startups since 2010. Two clients were acquired afterward — Mitralign by Edwards Lifesciences (tricuspid valve repair), ClarVista Medical by Alcon (intraocular lens). PAVmed's PortIO™ first-in-human results were published in The Journal of Vascular Access (Ulloa et al., 2026, DOI 10.1177/11297298261415957). Other named clients: Axoft, Newrotex, Avantec Vascular, Inspire Medical.
a timeline that varies by study (we confirm it per protocol). Onboarding to kickoff: varies by study; we confirm per protocol. Regulatory submission drafted: varies by study; we confirm per protocol. Ethics + regulator approval (parallel): varies by study; we confirm per protocol (Panama up to 20 business days (10 expedited) under Decreto Ejecutivo 21/2026, Colombia (varies by study; we confirm per protocol), Brazil (varies by study; we confirm per protocol)). Site activation + first patient: 1–2 weeks after approvals. Full study to last-patient-last-visit: 12 months under FIH-12™.
See country-by-country timelines
Yes — bioaccess® designs every clinical study with FDA submission in mind. We produce ICH E3-compliant clinical study reports, structured electronic data capture, and regulatory dossiers ready for IDE, IND, 510(k), De Novo, PMA, or HDE submissions. FDA Pre-Sub strategy is included in scope. You don't need a separate regulatory consultant unless your device has a unique reimbursement pathway requiring HTA strategy.
Yes — explicitly, under 21 CFR 812.28 (devices) and 21 CFR 312.120 (drugs and biologics). FDA acceptance of foreign clinical data is decided case by case and is never guaranteed; the FDA considers it when studies comply with ICH-GCP, have adequate ethics oversight, and are conducted by qualified investigators. bioaccess® has generated first-in-human data supporting U.S. regulatory strategy for clients including PAVmed, Axoft, and enVVeno Medical. We design every protocol to meet 21 CFR Part 11 data integrity requirements.
Four reasons: (1) study-specific ethics approval versus a timeline that varies by study (we confirm it per protocol) in the U.S. Budget depends on study design; we provide a study-specific quote. (3) Treatment-naive patient populations (~80%) producing cleaner data. (4) Bilingual ICH-GCP clinical staff with ACRP certification. The FDA may accept, case by case, the resulting data under 21 CFR 812.28. The cost and time savings preserve runway for venture-backed startups.
Pedro Martinez-Clark, MD (Co-founder & Chief Medical Officer) provides medical and regulatory oversight. William W. O'Neill, MD (Co-founder & Medical Director, MSCAI) provides scientific oversight. Julio G. Martinez-Clark, MBA (CEO) handles your weekly progress updates. Monica C. Mora (COO) leads regulatory operations. Plus a dedicated project manager, ACRP-certified clinical research associates, and the local PIs at your chosen sites. You meet the team at kickoff.
19 countries with active operations, including: Colombia (INVIMA), Brazil (ANVISA), Mexico (COFEPRIS), Argentina (ANMAT), Chile (ISP), Peru (DIGEMID), Panama (MINSA), Ecuador (ARCSA), El Salvador (SRS, successor to the DNM), and the Dominican Republic (MISPAS, through DIGEMAPS), plus Belize, Bolivia, Costa Rica, Guatemala, Honduras, Nicaragua, Paraguay (DINAVISA), Uruguay, and Venezuela. El Salvador's SRS succeeded the Dirección Nacional de Medicamentos in August 2024 (Ley de la Superintendencia de Regulación Sanitaria, art. 39, srs.gob.sv); DIGEMAPS is the specialized body of the Dominican Republic's Ministerio de Salud Pública (digemaps.gob.do). The optimal country depends on your device class, indication, and regulatory pathway — we recommend during the free Pre-FIH Readiness Assessment.
It can be assessed as one. The World Bank estimates about 18.7 million people in Guatemala for 2025, against about 11.5 million in the Dominican Republic and about 4.6 to 6.4 million in Panama, Costa Rica, and El Salvador (World Bank, World Development Indicators, SP.POP.TOTL). Trials are authorized by MSPAS through DRCPFA under Ministerial Agreement 206-2021, after approval by an authorized ethics committee. Population is not an enrollment forecast, and bioaccess® cites no completed Guatemala trials, sites, investigators, or patient numbers. Request a protocol-specific feasibility assessment.
Structural heart (transcatheter valves, mitral repair), vascular & interventional, neurotechnology (brain-computer interfaces, peripheral nerve repair), ophthalmology (intraocular lenses), spine, orthopedics, ENT, urology, wound care, radiology, dental implants, robotics, gene therapy, and radiopharmaceuticals (Lu-177, Ac-225, Ga-68 PET/CT). 50+ programs covering most therapeutic areas. If your device is novel, we've likely run a structurally similar program.
Browse cases by therapeutic area
Yes. Lu-177 and Ac-225 therapeutic programs, Ga-68 PET/CT imaging, and theranostic studies. We work with nuclear medicine sites that have on-site radiopharmacy and cyclotron access. The pathway combines U.S. regulatory anchoring (FDA Pre-Sub, IND) with execution at qualified Latin American radiopharma sites. We've run dose-escalation, biodistribution, dosimetry, and first-in-human radioligand therapy programs.
Radiopharmaceutical clinical trials
Book the free Pre-FIH Readiness Assessment. 30 minutes, no cost, no obligation. We'll tell you what's missing — whether it's a design history file gap, biocompatibility data, regulatory rationale, manufacturing quality system, or simply that your device class needs more bench testing first. If you're not ready, we'll say so. If you are, you'll leave with a country recommendation, indicative timeline, and per-patient budget range.
Free Pre-FIH Readiness Assessment
We manage end-to-end. bioaccess® coordinates with our insurance partner to procure the clinical trial liability policy each country requires. Several countries require locally constituted or locally enforceable cover (for example Argentina, Peru and Costa Rica), and limits are set by ethics committees, contracts and underwriting. Premiums are billed at vendor cost plus a 20% G&A handling fee.
Clinical trial insurance guide
About 2 hours per week. One 30-minute weekly status call. One async written update we send on Fridays — designed to be forwarded verbatim to your board. No daily standups, no Slack channels, no expectation that you track ethics-approval line items. Travel: zero required. Optional: one in-person trip to your lead site at study midpoint. All deliverables come back in English.
Standard adverse event reporting under ICH-GCP E6(R2). bioaccess® has a 24/7 safety hotline for investigators. Investigators report serious adverse events (SAEs) to the sponsor immediately, as ICH E6(R2) section 4.11.1 requires. Deadlines for reporting to ethics committees and the country regulator are set by each country's rules, so they vary by study; we confirm them per protocol. We pause enrollment until the safety review board clears continuation. Our medical director (William W. O'Neill, MD) reviews every SAE personally.
Two paths. Self-serve: spend 2 minutes in our cost & timeline calculator — you'll get a country recommendation, indicative timeline, and budget range. Or book a 30-minute strategy call with Julio (CEO). Either way: no commitment, no fee, no pressure. The next step after that is the free Pre-FIH Readiness Assessment, which is also no-cost. We don't ask for anything paid until you've decided bioaccess® is the right partner.